Safety Profile and Metabolic Effects of 14 Days of Treatment with DIO-902: Results of a Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial in Patients with Type 2 Diabetes Mellitus
Sherwyn L. Schwartz, Marc Rendell, Andrew J. Ahmann, Asha Thomas, Carlos J. Arauz-Pacheco, Bernice R. Welles
Dive into the research topics of 'Safety Profile and Metabolic Effects of 14 Days of Treatment with DIO-902: Results of a Phase IIa Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial in Patients with Type 2 Diabetes Mellitus'. Together they form a unique fingerprint.